Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract
Springer Editions (Verlag)
978-2-8178-0429-3 (ISBN)
Neuroendocrine tumors are fascinating multifaceted diseases that can primarily localize in many organs with various presentations. These tumors are rare but their increasing incidence renders likely that physicians caring for cancers may have either already faced or may be certainly exposed to diagnose and/or treat a patient with neuroendocrine tumors. Over the last years, novel therapeutic options have emerged for neuroendocrine tumors, profoundly challenging practices that had previously been the standards for decades. These include - but are not limited to - somatostatin analogues, targeted therapies such as tyrosine kinase and mTOR inhibitors, antiangiogenic compounds, but also peptide-receptor targeted therapy or radioembolization. This changing field has generated novel treatment algorithms to guide medical decisions. To better understand and handle the multidisciplinary approaches that are required for optimizing the care of neuroendocrine tumor patients, physicians are now looking for references from experts and comprehensive reviews summarizing current knowledge on treatments for patients with neuroendocrine tumors.
Co-editors: Prof. Eric Raymond is Head of Department of Medical Oncology at Bichat - Beaujon University Hospitals (Clichy - Paris, France). He is member of the ENETS' Executive Committee (European neuroendocrine tumors society) and active editorial board member of Targeted Oncology journal. Prof. Sandrine Faivre is deputy head Department of Medical Oncology at Bichat - Beaujon University Hospitals ((Clichy - Paris, France). She is editorial board member of Targeted Oncology journal. Prof. Philippe Ruszniewski is Head of Department of Gastroenterology and pancreatology at Beaujon University Hospitals (Clichy - Paris, France). He is vice-Chairman of the ENETS' Executive Committee.
Scintigraphy in Endocrine Tumors of the Gut.- Profiling the PI3K/Akt/Mtor Intracellular Pathway in Neuroendocrine Tumors.- Relevance of Angiogenesis in Neuroendocrine Tumors.- Advances with Somatostatin Analogues in Neuroendocrine Tumors: The Promise of Radionuclides in Neuroendocrine Tumors.- Streptozotocin-Based Chemotherapy is not History in Neuroendocrine Tumors.- Place of Surgical Resection in the Treatment Strategy in Neuroendocrine Tumors.- Endoscopic Resection of Gastrointestinal Neuroendocrine Tumors.- Liver-Targeting Therapies in Neuroendocrine Tumors.- Inhibition of Mtor in Neuroendocrine Tumors of the Digestive Tract.- Sunitinib in Pancreatic Neuroendocrine Tumors.- Clinical Management of Targeted Therapies in Neuroendocrine Tumors.- Imaging Tumor Response to Angiogenesis Inhibitors in Neuroendocrine Tumors.- Resistance to Targeted Therapies in Neuroendocrine Tumors.- New Anticancer Agents in Neuroendocrine Tumors.- Management of Symptoms and Patient Related Outcome Optimization in Neuroendocrine Tumors of the Digestive Tract.- Clinical Approaches of Emergencies in NET.
| Zusatzinfo | 24 Illustrations, color; 6 Illustrations, black and white; X, 236 p. 30 illus., 24 illus. in color. |
|---|---|
| Verlagsort | Paris |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Chirurgie |
| Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie | |
| Medizinische Fachgebiete ► Innere Medizin ► Gastroenterologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Schlagworte | angiogenesis • Carcinoid • Pancreatic Neuroendocrine Tumors • somatostatin receptors • tyrosine kinase inhibitors |
| ISBN-10 | 2-8178-0429-5 / 2817804295 |
| ISBN-13 | 978-2-8178-0429-3 / 9782817804293 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
